EMA — authorised 26 June 2006
- Marketing authorisation holder: BRISTOL-MYERS SQUIBB PHARMA EEIG
- Status: approved
EMA authorised Baraclude on 26 June 2006
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 26 June 2006.
BRISTOL-MYERS SQUIBB PHARMA EEIG holds the EU marketing authorisation.